Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains

Clinical Cancer Research

Volumn 12, Issue 18, 2006, Pages 5511-5519

  Ferrone, Cristina R ^a   Perales, Miguel Angel ^a,b   Goldberg, Stacie M ^a,b   Somberg, C Joy ^a   Hirschhorn Cymerman, Daniel ^a   Gregor, Polly D ^a   Turk, Mary Jo ^a,c   Ramirez Montagut, Teresa ^a,b   Gold, Jason S ^a   Houghton, Alan N ^a,b   Wolchok, Jedd D ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DNA VACCINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 21; PLASMID DNA; RECOMBINANT GAMMA INTERFERON; SECONDARY LYMPHOID TISSUE CHEMOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNITY; CANCER IMMUNIZATION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG BLOOD LEVEL; IMMUNIZATION; IMMUNOGENICITY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR REJECTION; VITILIGO;

ACUTE-PHASE REACTION; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD8; AUTOANTIGENS; CYTOKINES; GRAFT REJECTION; HYPOPIGMENTATION; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOTHERAPY, ACTIVE; INTERLEUKIN-12; MICE; MICE, INBRED C57BL; NEOPLASMS; PLASMIDS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TIME FACTORS; VACCINES, DNA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33749350789     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0979     Document Type: Article

References (48)

1. Chang J, Cho JH, Lee SW, Choi SY, Ha SJ, Sung YC. IL-12 priming during in vitro antigenic stimulation changes properties of CD8 T cells and increases generation of effector and memory cells. J Immunol 2004; 172:2818-26.
2. Barouch DH, Letvin NL, Seder RA. The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev 2004;202:266-74.
3. Calarota SA, Weiner DB. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol Rev 2004;199:84-99.
4. Prud'homme GJ. DNA vaccination against tumors. J Gene Med 2005;7:3-17.
5. Chang SY, Lee KC, Ko SY, Ko HJ, Kang CY. Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants. Int J Cancer 2004;111: 86-95.
6. Sumida SM, McKay PF, Truitt DM, et al. Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J Clin Invest 2004;114:1334-42.
7. Zheng LY, Mou L, Lin S, Lu RM, Luo EJ. Enhancing DNA vaccine potency against hantavirus by coadministration of interleukin-12 expression vector as a genetic adjuvant. Chin Med J (Engl) 2005;118: 313-9.
8. Sin JI, Kim J, Pachuk C, Weiner DB, Patchuk C. Interleukin 7 can enhance antigen-specific cytotoxic-T-lymphocyte and/or Th2-type immune responses in vivo. Clin Diagn Lab Immunol 2000;7:751-8.
9. Houghton AN. Cancer antigens: Immune recognition of self and altered self. J Exp Med 1994;180:1-4.
10. Weber LW, Bowne WB, Wolchok JD, et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 1998;102: 1258-64.
11. Bowne WB, Srinivasan R, Wolchok JD, et al. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 1999;190:1717-22.
12. Hawkins WG, Gold JS, Dyall R, et al. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery 2000;128: 273-80.
13. Bowne WB, Wolchok JD, Hawkins WG, et al. Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects. Cytokines Cell Mol Ther 1999;5:217-25.
14. Overwijk WW, Tsung A, Irvine KR, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998;188:277-86.
15. Gold JS, Ferrone CR, Guevara-Patino JA, et al. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol 2003;170: 5188-94.
16. + T cells. J Exp Med 2003;198:569-80.
17. Barouch DH, Santra S, Steenbeke TD, et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol 1998;161:1875-82.
18. Barouch DH, Craiu A, Kuroda MJ, et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci USA 2000;97:4192-7.
19. Barouch DH, Letvin NL. Cytokine-induced augmentation of DNA vaccine-elicited SIV-specific immunity in rhesus monkeys. Dev Biol (Basel) 2000; 104:85-92.
20. Barouch DH, McKay PF, Sumida SM, et al. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol 2003;77:8729-35.
21. + T lymphocyte responses. Eur J Immunol 2004; 34:1011-20.
22. Bloom MB, Perry-Lalley D, Robbins PF, et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997;185:453-9.
23. Ross HM, Weber LW, Wang S, et al. Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization. Clin Cancer Res 1997;3: 2191-6.
24. Peng LS, Penichet ML, Morrison SL. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J Immunol 1999;163:250-8.
25. Perales MA, Fantuzzi G, Goldberg SM, et al. GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines. Cytokines Cell Mol Ther 2002;7:125-33.
26. Dyall R, Bowne WB, Weber LW, et al. Heteroclitic immunization induces tumor immunity. J Exp Med 1998;188:1553-61.
27. Lewis JJ, Janetzki S, Schaed S, et al. Evaluation of CD8(+) T cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int J Cancer 2000;87:391-8.
28. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003;19:641-4.
29. Dinarello CA. IL-18: ATH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999;103:11-24.
30. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-46.
31. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor [NKSF], a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989;170:827-45.
32. Gately MK, Desai BB, Wolitzky AG, et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 [cytotoxic lymphocyte maturation factor]. J Immunol 1991;147:874-82.
33. O'Garra A, Murphy K. Role of cytokines in determining T-lymphocyte function. Curr Opin Immunol 1994; 6:458-66.
34. Waldmann TA, Dubois S, Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 2001;14: 105-10.
35. + T cells in vivo by IL-15. Immunity 1998; 8:591-9.
36. Parrish-Novak J, Foster DC, Holly RD, Clegg CH. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol 2002;72: 856-63.
37. + T cell expansion and function. J Exp Med 2005;201:139-48.
38. Kirk CJ, Hartigan-O'Connor D, Mule JJ. The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res 2001;61:8794-802.
39. Kirk CJ, Hartigan-O'Connor D, Nickoloff BJ, et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 2001;61:2062-70.
40. Leonard WJ, Spolski R. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol 2005;5:688-98.
41. Mori S, Nakano H, Aritomi K, Wang CR, Gunn MD, Kakiuchi T. Mice lacking expression of the chemokines CCL21-Serand CCL19 (pit mice) demonstrate delayed but enhanced T cell immune responses. J Exp Med 2001;193:207-18.
42. Kusakabe K, Xin KQ, Katoh H, et al. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. J Immunol 2000;164:3102-11.
43. Yamano T, Kaneda Y, Huang S, Hiramatsu SH, Hoon DS. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. Mol Ther 2006;13:194-202.
44. Barouch DH, Truitt DM, Letvin NL. Expression kinetics of the interleukin-2/immunoglobulin (IL-2/Ig) plasmid cytokine adjuvant. Vaccine 2004;22:3092-7.
45. Marchand M, van Baren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80:219-30.
46. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-7.
47. Lurquin C, Lethe B, De Plaen E, et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 2005;201:249-57.
48. Germeau C, Ma W, Schiavetti F, et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 2005;201:241-8.